MARILYN A MCLAUGHLIN

YORK, ME NPI 1891713632

General Payments — all program years on this page

$11,379.94

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 264
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $2,133.13 across 15 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $1,592.501
Food and Beverage $419.6312
Education $121.002

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $3,187.92140
2019 $2,080.7881
2020 $269.414
2021 $722.104
2022 $348.358
2023 $2,638.2512
2024 $2,133.1315

Records — PY2024 (15)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1078047832 Janssen Pharmaceuticals, Inc $22.00 05/23/2024 Education Undisputed 01/23/2026 View at CMS
1078735816 Janssen Biotech, Inc. $28.02 08/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101388488 E.R. Squibb & Sons, L.L.C. $107.78 10/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104508306 AstraZeneca Pharmaceuticals LP $1,592.50 10/01/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1104649155 AstraZeneca Pharmaceuticals LP $17.55 12/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104689388 AstraZeneca Pharmaceuticals LP $13.40 10/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105007265 ABBVIE INC. $99.00 04/25/2024 Education Undisputed 01/23/2026 View at CMS
1105007267 ABBVIE INC. $29.65 05/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105554248 AstraZeneca Pharmaceuticals LP $7.16 07/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135160634 Lilly USA, LLC $105.79 10/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135166880 Lilly USA, LLC $17.48 09/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144962866 Takeda Pharmaceuticals U.S.A., Inc. $23.10 04/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144962868 Takeda Pharmaceuticals U.S.A., Inc. $21.09 05/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144962870 Takeda Pharmaceuticals U.S.A., Inc. $19.11 10/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144962872 Takeda Pharmaceuticals U.S.A., Inc. $29.50 11/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.